EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy

Helen Dolk iD, Christine Damase-Michel iD, Joan Morris iD, Amanda Neville, Ester Garne iD, Sue Jordan iD, Anke Rissmann iD, Alessio Coi iD, Deirdre Folan, Dieuwke Broekstra iD, Jennifer M Broughan iD, Lea Bruneau iD und 16 weitere

Pharmacoepidemiology and Drug Safety · 2026-05 · 35 (5)

DOI: 10.1002/pds.70360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 29.04.2026. Verfasst von Helen Dolk und 27 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Ulster University, Londonderry, UK. Hauptthemen laut MEDLINE: Pharmacovigilance, Databases, Factual, Abnormalities, Drug-Induced, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seventh Framework Programme, Innovative Medicines Initiative, Ulster University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The evidence gap relating to the risk of congenital anomalies (CA) associated with first trimester medication exposure in pregnancy is well recognized.

Aims

We describe the EUROmediCAT network and databases, and the methodological approach to pregnancy pharmacovigilance. Material and Methods Multidisciplinary expertise includes CA diagnosis and epidemiology, pharmacoepidemiology, pharmacology and teratology. The EUROmediCAT central database comprises standardized data from 19 EUROCAT CA registries in 14 countries, including more than 40 000 CA cases 1995–2021 with first trimester medication exposure data recorded, and a population coverage of 14.6 million births, growing by more than 650 000 births per year. The distributed database enables federated data analysis across eight countries which can link data from CA registries to electronic healthcare data, with population coverage of up to 900 000 births per year for linkage to maternal prescriptions, of which 300 000 births per year for linkage also to data on all births.

Results

The databases have enabled a variety of study designs: case‐malformed control studies, cohort studies, disease cohort studies, signal detection studies, prevalence and ecological studies, and medication utilization studies.

Discussion

A key strength is that studies of CA risk can address accurately the specificity of risk by type of CA.

Conclusion

EUROmediCAT presents a unique data and expert resource for tackling the enormous evidence gap regarding the safety of medication during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceDatabases, FactualAbnormalities, Drug-InducedAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsFemaleHumansPregnancyRegistriesPregnancy Trimester, FirstEuropePharmacoepidemiology

Stichwörter der Autor:innen

congenital anomalydata sourcesmedication safetypharmacovigilancepregnancyregistries

Autor:innen und Institutionen

  • School of Medicine, Ulster University, Londonderry, UK.
  • Pharmacologie, Faculté de Médecine, Université Toulouse III, Centre Hospitalier Universitaire, INSERM, Center for Epidemiology and Research in POPulation Health (CERPOP), Toulouse, France.
  • Population Health Research Institute, St George's University of London, London, UK.
  • IMER Registry, Centre for Epidemiology and Clinical Research, University of Ferrara and Azienda ospedaliera e universitaria di Ferrara, Ferrara, Italy.
  • Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Odense, Denmark.
  • Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK.

ORCID-Profile: Helen Dolk, Christine Damase-Michel, Joan Morris, Ester Garne, Sue Jordan, Anke Rissmann, Alessio Coi, Dieuwke Broekstra, Jennifer M Broughan, Lea Bruneau, Clara Cavero-Carbonell, Elly den Hond, Miriam Gatt, Mika Gissler, Babak Khoshnood, Anna Latos Bielenska, Hedvig Nordeng, Ljubica Odak, Mary O'Mahony, Isabelle Perthus, J Luke Richardson, Florence Rouget, Joanna Sichitiu, David Tucker, Maria Loane

Förderung

  • Seventh Framework Programme
  • Innovative Medicines Initiative
  • Ulster University

Zitieren

APA

Dolk, H., Damase-Michel, C., Morris, J., Neville, A., Garne, E., Jordan, S., Rissmann, A., Coi, A., Folan, D., Broekstra, D., Broughan, J. M., Bruneau, L., Cavero-Carbonell, C., den Hond, E., Gatt, M., Gissler, M., Khoshnood, B., Bielenska, A. L., Nordeng, H., …, & Loane, M. (2026). The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy. Pharmacoepidemiology and Drug Safety, 35(5). https://doi.org/10.1002/pds.70360

Vancouver

Dolk H, Damase-Michel C, Morris J, Neville A, Garne E, Jordan S, et al. The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy. Pharmacoepidemiology and Drug Safety. 2026;35(5). doi:10.1002/pds.70360

BibTeX
@article{Dolk2026,
  author = {Dolk, Helen and Damase-Michel, Christine and Morris, Joan and Neville, Amanda and Garne, Ester and Jordan, Sue and Rissmann, Anke and Coi, Alessio and Folan, Deirdre and Broekstra, Dieuwke and Broughan, Jennifer M and Bruneau, Lea and Cavero-Carbonell, Clara and den Hond, Elly and Gatt, Miriam and Gissler, Mika and Khoshnood, Babak and Bielenska, Anna Latos and Nordeng, Hedvig and Odak, Ljubica and O'Mahony, Mary and Perthus, Isabelle and Richardson, J Luke and Rouget, Florence and Sichitiu, Joanna and Tucker, David and Zymak-Zakutnya, Natalya and Loane, Maria},
  title = {The EUROmediCAT Network and Databases: A Resource for Pharmacovigilance in Pregnancy},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  volume = {35},
  number = {5},
  doi = {10.1002/pds.70360}
}
Kostenlos starten →